Acrivon Therapeutics (ACRV) News Today $6.71 +0.02 (+0.30%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent ThesisDecember 12, 2024 | seekingalpha.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of "Buy" from BrokeragesAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has been given an average recommendation of "Buy" by the six research firms that are currently covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 1-year target price among brDecember 1, 2024 | marketbeat.comEquities Analysts Offer Predictions for ACRV FY2024 EarningsAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Research analysts at HC Wainwright dropped their FY2024 EPS estimates for shares of Acrivon Therapeutics in a research report issued on Wednesday, November 13th. HC Wainwright analyst E. Bodnar now expects that the company will post earningNovember 18, 2024 | marketbeat.comAcrivon Therapeutics Reports Promising Clinical Progress and Financial ResultsNovember 15, 2024 | markets.businessinsider.comAcrivon Therapeutics: Promising Clinical Data and Strategic Progress Justify Buy RatingNovember 14, 2024 | markets.businessinsider.comStrong Growth Outlook for Acrivon Therapeutics, Inc. Backed by Promising Pipeline and Strategic AdvancementsNovember 14, 2024 | markets.businessinsider.comAcrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 14, 2024 | finance.yahoo.comPromising Clinical Developments and Strong Financial Position Drive Buy Rating for Acrivon TherapeuticsNovember 14, 2024 | markets.businessinsider.comAcrivon Therapeutics: Promising Pipeline and Robust Financials Underpin Buy RatingNovember 14, 2024 | markets.businessinsider.comAcrivon Therapeutics (NASDAQ:ACRV) Price Target Cut to $27.00 by Analysts at BMO Capital MarketsBMO Capital Markets cut their price objective on shares of Acrivon Therapeutics from $28.00 to $27.00 and set an "outperform" rating on the stock in a report on Thursday.November 14, 2024 | marketbeat.comAcrivon Therapeutics (NASDAQ:ACRV) Given Buy Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $22.00 target price on shares of Acrivon Therapeutics in a report on Thursday.November 14, 2024 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Recommendation of "Buy" from AnalystsAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has earned an average recommendation of "Buy" from the six analysts that are covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that haveNovember 6, 2024 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest UpdateAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the recipient of a significant decline in short interest in the month of October. As of October 15th, there was short interest totalling 1,110,000 shares, a decline of 8.3% from the September 30th total of 1,210,000 shares. Based on an average daily trading volume, of 90,900 shares, the short-interest ratio is currently 12.2 days. Approximately 5.1% of the company's shares are sold short.October 30, 2024 | marketbeat.comAcrivon Therapeutics: Promising Innovations in WEE1/PKMYT1 Inhibition and AP3 Platform Drive Buy RatingOctober 29, 2024 | markets.businessinsider.comAcrivon Therapeutics: Buy Rating Driven by Promising Oncology Advancements and Strategic PositioningOctober 29, 2024 | markets.businessinsider.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Down 5.5% in SeptemberAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the target of a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,210,000 shares, a drop of 5.5% from the September 15th total of 1,280,000 shares. Based on an average trading volume of 93,600 shares, the days-to-cover ratio is presently 12.9 days. Currently, 5.6% of the company's stock are sold short.October 17, 2024 | marketbeat.comAcrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)October 16, 2024 | globenewswire.comAcrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology PipelineOctober 12, 2024 | finance.yahoo.comAcrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent ActivityOctober 11, 2024 | globenewswire.comAcrivon Therapeutics (NASDAQ:ACRV) Stock, Short Interest ReportOctober 7, 2024 | benzinga.comMarshall Wace LLP Raises Stock Holdings in Acrivon Therapeutics, Inc. (NASDAQ:ACRV)Marshall Wace LLP lifted its holdings in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) by 58.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 948,866 shares of the company's stock afOctober 2, 2024 | marketbeat.comPerceptive Advisors LLC Has $31.09 Million Stock Position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV)Perceptive Advisors LLC lifted its position in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) by 78.2% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,360,858 shares of the company's stocSeptember 30, 2024 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 24.3% in SeptemberAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the recipient of a large growth in short interest in September. As of September 15th, there was short interest totalling 1,280,000 shares, a growth of 24.3% from the August 31st total of 1,030,000 shares. Currently, 5.9% of the company's shares are short sold. Based on an average daily volume of 101,600 shares, the days-to-cover ratio is currently 12.6 days.September 28, 2024 | marketbeat.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Position Raised by Sands Capital Ventures LLCSands Capital Ventures LLC grew its position in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) by 28.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,122,605 shares of tSeptember 21, 2024 | marketbeat.comAcrivon shares maintain buy rating on positive analyst ratingSeptember 18, 2024 | uk.investing.comAcrivon Therapeutics maintains Buy rating from H.C. Wainwright with steady price targetSeptember 18, 2024 | uk.investing.comBreaking Down Acrivon: Deep Dive Into Revenue, Profitability, And ProspectsSeptember 18, 2024 | seekingalpha.comAcrivon Therapeutics: Buy Rating Justified by Promising Clinical Data and Strategic Research InitiativesSeptember 18, 2024 | markets.businessinsider.comLadenburg Thalmann Upgrades Acrivon Therapeutics (ACRV)September 17, 2024 | msn.comTD Cowen Remains a Buy on Acrivon Therapeutics, Inc. (ACRV)September 17, 2024 | markets.businessinsider.comJMP Securities Reaffirms Market Outperform Rating for Acrivon Therapeutics (NASDAQ:ACRV)JMP Securities reiterated a "market outperform" rating and set a $17.00 price target on shares of Acrivon Therapeutics in a research report on Monday.September 16, 2024 | marketbeat.comAcrivon Therapeutics' (ACRV) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $22.00 target price on shares of Acrivon Therapeutics in a report on Monday.September 16, 2024 | marketbeat.comAcrivon Therapeutics (NASDAQ:ACRV) Raised to "Buy" at LADENBURG THALM/SH SHLADENBURG THALM/SH SH raised Acrivon Therapeutics from a "neutral" rating to a "buy" rating and set a $16.00 target price on the stock in a report on Monday.September 16, 2024 | marketbeat.comAcrivon Therapeutics, Inc.: Strong Buy on Robust Clinical Data and Strategic Market PositioningSeptember 16, 2024 | markets.businessinsider.comAcrivon Therapeutics, Inc.: Strong Buy on Positive ACR-368 Therapy Data and Market PositioningSeptember 15, 2024 | markets.businessinsider.comAcrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data AnalysisSeptember 14, 2024 | globenewswire.comAcrivon Therapeutics to Present at the Cantor Global Healthcare ConferenceSeptember 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Acrivon Therapeutics Amid Promising Cancer Program Prospects and Strong Market PotentialSeptember 9, 2024 | markets.businessinsider.comAcrivon Therapeutics (NASDAQ:ACRV) Receives Buy Rating from Piper Sandler CompaniesPiper Sandler Companies restated a "buy" rating and issued a $30.00 target price on shares of Acrivon Therapeutics in a research note on Friday.September 6, 2024 | marketbeat.comWe're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash WiselySeptember 5, 2024 | finance.yahoo.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Recommendation of "Moderate Buy" by AnalystsAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has received an average recommendation of "Moderate Buy" from the six research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the comAugust 23, 2024 | marketbeat.comAcrivon Therapeutics: A Buy Rating Justified by Clinical Advances and Financial StabilityAugust 16, 2024 | markets.businessinsider.comBMO maintains Outperform rating on Acrivon Therapeutics sharesAugust 16, 2024 | uk.investing.comAcrivon Therapeutics (NASDAQ:ACRV) Posts Earnings ResultsAcrivon Therapeutics (NASDAQ:ACRV - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.60) by $0.08.August 14, 2024 | marketbeat.comAcrivon Therapeutics, Inc.: Strong Buy Rating on Robust Financials and Promising Clinical DataAugust 13, 2024 | markets.businessinsider.comPromising Acrivon Trial Results and Market Opportunity Support Buy RatingAugust 13, 2024 | markets.businessinsider.comAcrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsAugust 13, 2024 | finance.yahoo.comBuy Rating Affirmed on Acrivon Therapeutics Amid Anticipated Clinical Updates and Novel Treatment ApproachesAugust 13, 2024 | markets.businessinsider.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Rating of "Moderate Buy" by BrokeragesAcrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to thJuly 4, 2024 | marketbeat.comAcrivon Therapeutics (NASDAQ:ACRV) Trading 1% Higher Acrivon Therapeutics (NASDAQ:ACRV) Stock Price Up 1%July 2, 2024 | marketbeat.com Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED. Click here to see the details because I believe a lot of people will get rich. ACRV Media Mentions By Week ACRV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACRV News Sentiment▼0.000.59▲Average Medical News Sentiment ACRV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACRV Articles This Week▼02▲ACRV Articles Average Week Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Immatics News Today uniQure News Today Replimune Group News Today 89bio News Today Pliant Therapeutics News Today Relay Therapeutics News Today Anavex Life Sciences News Today Immunome News Today Kura Oncology News Today Keros Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACRV) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACRV Stock Alerts